Q2 2025 Mentice AB Earnings Call Transcript
Key Points
- Mentice AB (OSTO:MNTC) received FDA and Brazilian clearance for their Ankyras® product, enhancing their product offering in these markets.
- The company implemented a strategic workforce alignment, expected to save approximately SEK25 million annually.
- Mentice AB (OSTO:MNTC) has strong partnerships with 27 of the top 30 medical device industry companies, which supports their business growth.
- The rights issue was well-received, with 66% underwriting, indicating strong support from shareholders and the board.
- Recurring revenues increased by 9% compared to the previous year, with significant growth in software licenses.
- Net sales for the rolling 12 months decreased by 7% compared to the previous year.
- Order intake declined by 3% due to weaker demand in the APAC region.
- The company reported an EBITDA loss of SEK8 million for the quarter, impacted by costs related to strategic realignment.
- Operational cash flow was negative, at minus SEK7 million, affected by the quarterly results.
- The APAC market showed a significant drop in order intake, offsetting growth in other regions.
I'm an Equity Research Analyst at DNB Carnegie Bank. With me, I have Frans Venker, CEO, and Ulrika Drotz, CFO of Mentice, to present the Mentice Q2 earnings. Welcome, Frans, Ulrika.
Thank you, Richard. Thanks for having us.
So, the scene is yours.
Thank you, Richard. So we are going to present the Q2 interim basically report which we have, and the earnings call today. So myself, Frans Venker, together with Ulrika Drotz, our CFO for Mentice, and what we have today is first of all, highlights in an overview which I will present the financial results by Ulrika. I have some concluding remarks and then we have questions and answers effectively what we see.
Key strategic measures that we implemented within the Mentice organization in a cautious market, so we had [net sales of SEK63 million]. What we saw was that the rolling 12 months
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
